环十二烷基氯甲酸酯 | 65676-18-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 环十二烷基氯甲酸酯
• 英文名称: Cyclododecyl chloroformate
• 英文别名: cyclododecyl carbonochloridate
• CAS: 65676-18-8
• 化学式: C₁₃H₂₃ClO₂
• 分子量: 246.777
• InChiKey: RUVAAQJZCQKNAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-phenethyl-α-methyl-(RS)-tryptophanamine 、 环十二烷基氯甲酸酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 (+/-)-carbamic acid<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<(2-phenylethyl)amino>ethyl>cyclododecyl ester
  参考文献：
  名称：

  Rationally designed ‘dipeptoid’ analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyl-tryptophan derivatives

  摘要：

  The structure-affinity relationships (SAR) between the N-terminii of a series of alpha-methyl-tryptophanylphenethylamide derivatives and the cholecystokinin (CCK) B receptor are discussed. A series of compounds with the general formula R-X-alpha-methyl-tryptophanylphenethylamide was prepared, where R is a cycloalkyl, a bicycloalkyl or a tricycloalkyl group and X is a urethane, thiourethane, amide, urea or a sulphinamide linking group. The CCK-B receptor binding affinities of these are discussed. The SAR form part of a systematic program for the rational design of 'dipeptoid' analogues of the neuropeptide CCK. Beginning with 1,1-dimethylpropyl (+/-)-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate (IC50 = 4720 nM on CCK-B binding affinity) the N-terminal moiety was systematically changed for groups of varying size, shape and lipophilicity until the optimal N-terminal group was obtained and the favoured linking group chosen, resulting in the compound tricyclo[3.3.1.1(3,7)]dec-2-yl(R)-[(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate with an IC50 = 32 nM on CCK-B receptor binding affinity.

  DOI：

  10.1016/0223-5234(93)90077-r
• 作为产物：
  描述：

  三光气 、 环十二醇 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 环十二烷基氯甲酸酯
  参考文献：
  名称：

  Rationally designed ‘dipeptoid’ analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyl-tryptophan derivatives

  摘要：

  The structure-affinity relationships (SAR) between the N-terminii of a series of alpha-methyl-tryptophanylphenethylamide derivatives and the cholecystokinin (CCK) B receptor are discussed. A series of compounds with the general formula R-X-alpha-methyl-tryptophanylphenethylamide was prepared, where R is a cycloalkyl, a bicycloalkyl or a tricycloalkyl group and X is a urethane, thiourethane, amide, urea or a sulphinamide linking group. The CCK-B receptor binding affinities of these are discussed. The SAR form part of a systematic program for the rational design of 'dipeptoid' analogues of the neuropeptide CCK. Beginning with 1,1-dimethylpropyl (+/-)-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate (IC50 = 4720 nM on CCK-B binding affinity) the N-terminal moiety was systematically changed for groups of varying size, shape and lipophilicity until the optimal N-terminal group was obtained and the favoured linking group chosen, resulting in the compound tricyclo[3.3.1.1(3,7)]dec-2-yl(R)-[(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate with an IC50 = 32 nM on CCK-B receptor binding affinity.

  DOI：

  10.1016/0223-5234(93)90077-r

文献信息

• METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS
  申请人：Fetzer Oliver S.

  公开号：US20140328918A1

  公开（公告）日：2014-11-06

  Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

  本文描述了使用聚合物-药剂颗粒和环糊精聚合物药剂偶联物的组合方法来治疗受试者。本文中的方法可用于治疗被诊断为癌症、心血管疾病、自身免疫性疾病或炎症性疾病的受试者。本文还描述了包含聚合物-药剂颗粒和环糊精聚合物药剂偶联物的组合物、剂型和套装。
• Novel hydroxy-peroxides and their uses
  申请人：ATOCHEM NORTH AMERICA, INC.

  公开号：EP0381135A2

  公开（公告）日：1990-08-08

  Novel hydroxy peroxides of the Structure A [wherein R-, -R11- and -X- are as defined in the Summary of the Invention Section], having 10 hour half-life temperatures of 85-100 °C, the processes for their preparation, and the use of these novel compositions in curing of unsaturated polyester resins and in initiating polymerization of ethylenically unsaturated monomers.

  结构 A 的新型羟基过氧化物 [其中 R-、-R11- 和 -X- 的定义见发明概述部分]、 其半衰期为 10 小时，温度为 85-100 °C，其制备工艺，以及这些新型组合物在固化不饱和聚酯树脂和引发乙烯基不饱和单体聚合中的用途。
• 1-Cyclohexyl-1-methylethylperoxy carbonates, method for production thereof, and uses therefor
  申请人：NOF CORPORATION

  公开号：EP0610016A1

  公开（公告）日：1994-08-10

  A 1-cyclohexyl-1-methylethylperoxy carbonate represented by the formula: (wherein n₁ stands for 1 or 2 and, when n₁ is 1, R₁ stands for an alkyl group of up to 14 carbon atoms, an aralkyl group of up to 14 carbon atoms, an alkoxyalkyl group of up to 14 carbon atoms, a cycloalkyl group of up to 14 carbon atoms, or an aryl group of up to 14 carbon atoms, and when n₁ is 2, R₁ stands for an alkylene group of up to 16 carbon atoms, an aralkylene group of up to 16 carbon atoms, an oxaalkylene group of up to 16 carbon atoms, a cycloalkylene group of up to 16 carbon atoms, or a phenylene group of up to 16 carbon atoms) is a novel compound. It is produced by causing a chloroformate represented by the formula: (wherein n₂ has the same meaning as n₁ in the preceding formula) to react with 1-cyclohexyl-1-methylethylhydroperoxide. It is useful as a polymerization initiator for a vinyl monomer, a curing agent for an unsaturated polyester resin and a crosslinking agent for a polymer.

  一种 1-环己基-1-甲基乙基过氧化碳酸酯，由式表示： (其中 n₁ 代表 1 或 2，当 n₁ 为 1 时，R₁ 代表碳原子数不超过 14 个的烷基、碳原子数不超过 14 个的芳基、碳原子数不超过 14 个的烷氧基烷基、碳原子数不超过 14 个的环烷基或碳原子数不超过 14 个的芳基、当 n₁ 为 2 时，R₁ 代表碳原子数不超过 16 个的亚烷基、碳原子数不超过 16 个的芳烷基、碳原子数不超过 16 个的氧烷基、碳原子数不超过 16 个的环烷基或碳原子数不超过 16 个的亚苯基）是一种新型化合物。它是通过使由以下式子表示的氯甲酸酯生成的： (其中 n₂ 与上式中的 n₁ 意义相同）与 1-环己基-1-甲基乙基过氧化氢反应而制得。它可用作乙烯基单体的聚合引发剂、不饱和聚酯树脂的固化剂和聚合物的交联剂。
• Novel oxalic acid peroxide compositions and uses
  申请人：ELF ATOCHEM NORTH AMERICA, INC.

  公开号：EP0850927A1

  公开（公告）日：1998-07-01

  A novel peroxide composition of Structure A, and use of the novel oxalic acid peroxide composition of Structure A as an initiator; a) for curing of unsaturated polyester resins, b) for polymerizing ethylenically unsaturated monomers, c) for crosslinking of polyolefins, d) for curing of elastomers, e) for modifying polyolefins, f) for grafting of vinyl monomers onto polymer backbones and g) for compatibilizing blends of two or more incompatible polymers are disclosed.

  结构 A 的新型过氧化物组合物 结构 A 的新型草酸过氧化物组合物作为引发剂；a) 用于不饱和聚酯树脂的固化；b) 用于乙烯基不饱和单体的聚合；c) 用于聚烯烃的交联；d) 用于弹性体的固化；e) 用于聚烯烃的改性；f) 用于乙烯基单体在聚合物骨架上的接枝；g) 用于两种或两种以上不相容聚合物混合物的相容。
• COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES
  申请人：Cerulean Pharma Inc.

  公开号：EP3566719A1

  公开（公告）日：2019-11-13

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  本文提供了有关使用 CDP-治疗剂共轭物治疗自身免疫性疾病、炎症性疾病或癌症的方法。还提供了 CDP-治疗剂共轭物、包含 CDP-治疗剂共轭物的颗粒和包含 CDP-治疗剂共轭物的组合物。